Derivatives of leflunomide's active metabolite a77-1726, the malononitrilamides (MNAs), prevent the development of experimental arthritis

International Journal of Immunotherapy

Volumn 14, Issue 4, 1997, Pages 177-184

  Schorlemmer, H U ^a   Schleyerbach, R ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; COLLAGEN TYPE 2; DRUG METABOLITE; LEFLUNOMIDE; RHEUMATOID FACTOR;

ADJUVANT ARTHRITIS; ANIMAL EXPERIMENT; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; CONTROLLED STUDY; LYMPH NODE; NONHUMAN; PANNUS; PAW EDEMA; POLYARTHRITIS; RAT; SPLENOMEGALY; SYNOVIUM; T LYMPHOCYTE;

EID: 0032453856     PISSN: 02559625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Weinblatt M., Kremer J., Coblyn J., et al. Leflunomide plus methotrexate in refractory rheumatoid arthritis: a pilot study. Arth. Rheum., 40, 974, 1997.
2. Rozman B. Clinical experience with leflunomide in rheumaotid arthritis. J. Rheumatol., 25, 27,1998.
3. Williamson R.A., Yea C.M., Robson P.A., et al. Dihydroorotate dehydrogenase is a high affinity binding protein for A77-1726 and mediator of a range of biological effects of the immunomodulatory compound. J. Biol. Chem., 270, 22467, 1995.
4. Kuo E.A., Hambleton P.T., Kay O.P., et al. Synthesis, structure-activity relationships, and pharmacokinetic properties of dihydroorotate dehydrogenase inhibitors: 2-cyano-3-cyclopropyl-3-hydroxy-N-[3-methyl-4-(tri!/uoromethyl)phenyl] propenamide and related compounds. J. Med. Chem., 39, 4608, 1996.
5. Suva H.T., Morris R.E. Leflunomide and malononitrilamides. Exp. Opin. Invest. Drugs, 6, 51, 1997.
6. Kurrle R., Bartlett R., Ruuth E., Lauffer L, Schorlemmer H.U. Malononitrilamides inhibit T- and B-cell responsiveness. Transplant. Proc., 28, 3053, 1996.
7. Czech J., Schorlemmer H.U., Schwab W. Effect of malononitrilamides on human bone marrow. Transplant. Proc., 28, 3051, 1996.
8. Kurrle R., Ruuth E., Bartlett R., Lauffer L., Schorlemmer H.U. Malononitrilamides inhibit T- and B-cell responsiveness in different species. Transplant. Proc., 29, 1302, 1997.
9. Suva H.T., Morris R.E. Leflunomide and malononitrilamides. Am. J. Med. Sci., 313, 289, 1997.
10. Gregory C.R., Suva H.T. Patz J.D., Morris R.E. Comparative effects of malononitrilamide analogs of leflunomide on whole blood lymphocyte stimulation in humans, rhesus macaques, cats, dogs, and rats. Transplant. Proc., 30, 1047, 1998.
11. Czech J., Schwab W., Schorlemmer H.U. A molecular mechanism for the direct antiproliferative effect of malononitrilamides (MNAs) on vascular smooth muscle cells. Transplantation, 65, S39, 1998.
12. Slauson S., Suva H, Sherwood S., Morris R.E. Flow cytometric (FCM) analysis of the molecular mechanisms of immunosuppressive action of the active metabolite of leflunomide and its malononitrilamide (MNA) analogs in a novel whole blood assay. Transplantation, 65, S134,1998.
13. Schorlemmer H.U., Ruuth E., Kurrle R. Regulation of alloreactivity in the popliteal lymph node assay by the new immunosuppressants:malononitrilamides. Transpl. Int., 11, S448, 1998.
14. Schorlemmer H.U., Bartlett R.R., Kurrle R. Inhibition of alloreactivity in the popliteal lymph node assay by malononitrilamides. Transplant. Proc., 30, 968,1998.
15. Suva H.T., Slauson S., Shorthouse R., Lôffler M., Morris R.E. Inhibition of dihydroorotate dehydrogenase (DHODH) is the molecular mechanism of immunosuppression by the malononitrilamides (MNAs) in vivo. Transplantation, 65, S28, 1998.
16. Schorlemmer H., Bartlett R., Kurrle R. Malononitrilamides: a new strategy of immunosuppression for a/to- and xenotransplantation. Transplant. Proc., 30, 884, 1998.
17. Schorlemmer H.U., Bartlett R.R. Prevention of the development of murine systemic lupus erythematosus (SLE)-like diseases by the malononitrilamides MNA 279 and MNA 715. Inflamm. Res., 46, S167, 1997.
18. Schorlemmer H.U., Bartlett R.R. Effects of the immunosuppressive malononitrilamides on rheumatoid and systemic lupus erythematosus (SLE)-like disease. Int. J. Immunotherapy, 13, 1, 1997.
19. Schorlemmer H.U., Bartlett R.R. Therapeutic activity of malononitrilamides (MNA 279 and MNA 715) on acute and chronic, relapsing, experimental allergic encephalomyelitis (EAE). Drugs Exptl. Clin. Res., 23, 175, 1997.
20. Schorlemmer H.U., Bartlett R.R. Malononitrilamides (MNA 279 and MNA 715) have therapeutic activity in acute and chronic relapsing experimental allergic encephalomyelitis (EAE). Inflamm. Res., 46, S163, 1997.
21. Schorlemmer H.U., Kurrle R., Bartlett R.R. The new immunosuppressants, the malononitrilamides MNA 279 and MNA 715, inhibit various graft-vs.-host diseases (GvHD) in rodents. Drugs Exptl. Clin. Res., 23, 167, 1997.
22. Perper R., Alvarez B., Colombo C., Schröder H. The use of a standardized adjuvant arthritis assay to differentiate between antiinflammatory and immunosuppressive agents. Proc. Soc. Exp. Biol. Med., 137, 506, 1971.
23. Mladenovic V., Domljan I., Rozman B., et al. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Arth. Rheum., 38, 1595, 1995.
24. Smolen J.S., Kalden J.R., Rozman B., Scott D.L., Rosenburg R., Löw-Friedrich I. Efficacy and safety of leflunomide versus placebo and sulfosalazine in rheumatoid arthritis: a double blind, randomized, pivotal, phase III trial. Rheum. Eur., 27, 110, 1998.